MétaCan
Menu
Back to cohort
Record W4411011492 · doi:10.1016/j.cllc.2025.05.009

Evaluating Diagnostic and Treatment Timelines for ALK-Positive NSCLC Patients: Results From a Global Registry

2025· article· en· W4411011492 on OpenAlexaboutno aff
Nicholas Thuo, Wei Chen, Faten Abda, Aula Alqased, Swara Chindhade, Yasmin Snounu, Sadia Yaakov, Colin Barton, Matthew Thompson, Kenneth W. Culver, Morhaf Al Achkar

Bibliographic record

VenueClinical Lung Cancer · 2025
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Treatments and Mutations
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineCrizotinibTimelineLung cancerInternal medicineOncologyIntensive care medicine

Abstract

fetched live from OpenAlex

Background Anaplastic Lymphoma Kinase (ALK)-positive non-small cell lung cancer (NSCLC) primarily affects younger, non-smoking individuals. Tyrosine kinase inhibitors (TKIs) have improved survival. While timely diagnosis and TKI initiation are critical, global data on diagnostic and treatment timelines remain scarce. This study examines key intervals from the first medical visit to diagnosis and treatment, and factors linked to delays. Methods The ALK Life Study is a longitudinal observational study of ALK-positive NSCLC patients, with data collected via online surveys from September 2022 to November 2024. Patients were recruited through support groups, newsletters, and oncologist referrals. Descriptive statistics and multivariable regression identified factors influencing timelines. Results A total of 1,288 patients from 71 countries completed the survey. The median age at diagnosis was 52 years, 52% from the U.S., and 28% with a smoking history. For all patients, the median time from first medical visit to diagnosis (DOD) was 45 days (IQR: 16–120). For stage IIIC/IV patients, the median time from diagnosis to TKI treatment (DDT) was 30 days (IQR: 17–49). Older ages at the first visit were linked to shorter DOD, while more symptoms increased DOD. For advanced-stage patients, older age, GERD, and high blood pressure prolonged DDT, while coughing up blood and voice changes shortened it. Recent diagnosis year and residence in Canada were tied to shorter DDT. Conclusions Younger age, specific comorbidities, non-specific symptoms, and geographic factors lengthen intervals to diagnosis and treatment. Raising awareness of ALK-positive NSCLC in younger patients could improve diagnosis timelines and outcomes. Micro Abstract The ALK Life Study analyzed diagnostic and treatment timelines in 1,288 ALK-positive NSCLC patients from 71 countries. The median time to diagnosis was 45 days, and time to TKI treatment was 30 days for advanced-stage patients. Younger age, comorbidities, and geographic factors were linked to delays. Outcomes may be improved by raising awareness amongst clinicians of the frequency of ALK-positive NSCLC in younger populations

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.003
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.434
Threshold uncertainty score0.538

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.052
GPT teacher head0.509
Teacher spread0.456 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueClinical Lung CancerSame topicLung Cancer Treatments and MutationsFrench-language works237,207